• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

血栓性血小板减少性紫癜恢复后长期随访中出现多种主要合并症和死亡率增加。

Multiple major morbidities and increased mortality during long-term follow-up after recovery from thrombotic thrombocytopenic purpura.

机构信息

Department of Biostatistics and Epidemiology, College of Public Health.

出版信息

Blood. 2013 Sep 19;122(12):2023-9; quiz 2142. doi: 10.1182/blood-2013-04-496752. Epub 2013 Jul 9.

DOI:10.1182/blood-2013-04-496752
PMID:23838348
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3778546/
Abstract

Recovery from acute episodes of thrombotic thrombocytopenic purpura (TTP) appears complete except for minor cognitive abnormalities and risk for relapse. The Oklahoma TTP-HUS (hemolytic uremic syndrome) Registry enrolled 70 consecutive patients from 1995 to 2011 with ADAMTS13 activity <10% at their initial episode; 57 survived, with follow-up through 2012. The prevalence of body mass index (BMI), glomerular filtration rate (GFR), urine albumin/creatinine ratio (ACR), hypertension, major depression, systemic lupus erythematosus (SLE), and risk of death were compared with expected values based on the US reference population. At initial diagnosis, 57 survivors had a median age of 39 years; 45 (79%) were women; 21 (37%) were black; BMI and prevalence of SLE (7%) were greater (P < .001) than expected; prevalence of hypertension (19%; P = .463) was not different. GFR (P = .397) and ACR (P = .793) were not different from expected values. In 2011-2012, prevalence of hypertension (40% vs 23%; P = .013) and major depression (19% vs 6%; P = .005) was greater than expected values. Eleven patients (19%) have died, a proportion greater than expected compared with US and Oklahoma reference populations (P < .05). TTP survivors may have greater risk for poor health and premature death.

摘要

除了轻微的认知异常和复发风险外,急性血栓性血小板减少性紫癜(TTP)发作的患者似乎已完全康复。俄克拉荷马 TTP-HUS(溶血性尿毒症综合征)登记处从 1995 年至 2011 年共登记了 70 例连续患者,这些患者在初次发作时 ADAMTS13 活性<10%;57 例存活,随访至 2012 年。将体重指数(BMI)、肾小球滤过率(GFR)、尿白蛋白/肌酐比值(ACR)、高血压、重度抑郁症、系统性红斑狼疮(SLE)的患病率以及死亡率与基于美国参考人群的预期值进行了比较。在初次诊断时,57 例幸存者的中位年龄为 39 岁;45 例(79%)为女性;21 例(37%)为黑人;BMI 和 SLE(7%)的患病率较高(P<0.001);高血压(19%;P=0.463)的患病率无差异。GFR(P=0.397)和 ACR(P=0.793)与预期值无差异。2011-2012 年,高血压(40%比 23%;P=0.013)和重度抑郁症(19%比 6%;P=0.005)的患病率高于预期值。11 例患者(19%)死亡,与美国和俄克拉荷马州参考人群相比,这一比例高于预期(P<0.05)。TTP 幸存者的健康状况和过早死亡风险可能更大。

相似文献

1
Multiple major morbidities and increased mortality during long-term follow-up after recovery from thrombotic thrombocytopenic purpura.血栓性血小板减少性紫癜恢复后长期随访中出现多种主要合并症和死亡率增加。
Blood. 2013 Sep 19;122(12):2023-9; quiz 2142. doi: 10.1182/blood-2013-04-496752. Epub 2013 Jul 9.
2
Life after acquired thrombotic thrombocytopenic purpura: morbidity, mortality, and risks during pregnancy.获得性血栓性血小板减少性紫癜后的生活:发病率、死亡率和妊娠期间的风险。
J Thromb Haemost. 2015 Jun;13 Suppl 1:S216-22. doi: 10.1111/jth.12953.
3
Children and adults with thrombotic thrombocytopenic purpura associated with severe, acquired Adamts13 deficiency: comparison of incidence, demographic and clinical features.与严重获得性 ADAMTS13 缺乏相关的血栓性血小板减少性紫癜的儿童和成人:发病率、人口统计学和临床特征比较。
Pediatr Blood Cancer. 2013 Oct;60(10):1676-82. doi: 10.1002/pbc.24612. Epub 2013 Jun 1.
4
Different disparities of gender and race among the thrombotic thrombocytopenic purpura and hemolytic-uremic syndromes.血栓性血小板减少性紫癜和溶血尿毒综合征中性别和种族的不同差异。
Am J Hematol. 2010 Nov;85(11):844-7. doi: 10.1002/ajh.21833.
5
Pregnancy outcomes following recovery from acquired thrombotic thrombocytopenic purpura.获得性血栓性血小板减少性紫癜恢复后的妊娠结局。
Blood. 2014 Mar 13;123(11):1674-80. doi: 10.1182/blood-2013-11-538900. Epub 2014 Jan 7.
6
The incidence of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: all patients, idiopathic patients, and patients with severe ADAMTS-13 deficiency.血栓性血小板减少性紫癜-溶血性尿毒症综合征的发病率:所有患者、特发性患者以及伴有严重ADAMTS-13缺乏的患者。
J Thromb Haemost. 2005 Jul;3(7):1432-6. doi: 10.1111/j.1538-7836.2005.01436.x.
7
The Oklahoma Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome (TTP-HUS) Registry: a community perspective of patients with clinically diagnosed TTP-HUS.俄克拉荷马血栓性血小板减少性紫癜-溶血性尿毒症综合征(TTP-HUS)登记处:临床诊断为TTP-HUS患者的社区视角。
Semin Hematol. 2004 Jan;41(1):60-7. doi: 10.1053/j.seminhematol.2003.10.001.
8
Diagnostic and therapeutic challenges in the thrombotic thrombocytopenic purpura and hemolytic uremic syndromes.血栓性血小板减少性紫癜和溶血尿毒综合征的诊断和治疗挑战。
Hematology Am Soc Hematol Educ Program. 2012;2012:604-9. doi: 10.1182/asheducation-2012.1.604.
9
The thrombotic thrombocytopenic purpura and hemolytic uremic syndromes: evaluation, management, and long-term outcomes experience of the Oklahoma TTP-HUS Registry, 1989-2007.血栓性血小板减少性紫癜和溶血性尿毒症综合征:1989 - 2007年俄克拉荷马州血栓性血小板减少性紫癜-溶血性尿毒症综合征登记处的评估、管理及长期预后经验
Kidney Int Suppl. 2009 Feb(112):S52-4. doi: 10.1038/ki.2008.622.
10
Sporadic bloody diarrhoea-associated thrombotic thrombocytopenic purpura-haemolytic uraemic syndrome: an adult and paediatric comparison.散发性血性腹泻相关的血栓性血小板减少性紫癜-溶血尿毒综合征:成人与儿童的比较
Br J Haematol. 2008 May;141(5):696-707. doi: 10.1111/j.1365-2141.2008.07116.x. Epub 2008 Apr 15.

引用本文的文献

1
Thrombotic thrombocytopenic purpura: early diagnosis and effective treatment in 2025.血栓性血小板减少性紫癜:2025年的早期诊断与有效治疗
Intensive Care Med. 2025 Jul 3. doi: 10.1007/s00134-025-07981-3.
2
A Descriptive 5-Year Analysis of the Demographics and Therapies for Patients With Immune Thrombotic Thrombocytopenic Purpura in the USA: A Multicenter Study of 390 Disease Episodes From 2017 to 2021.美国免疫性血栓性血小板减少性紫癜患者的人口统计学和治疗方法的描述性5年分析:一项对2017年至2021年390例疾病发作的多中心研究
J Clin Apher. 2025 Apr;40(2):e70017. doi: 10.1002/jca.70017.
3
Cost-effectiveness of caplacizumab in immune thrombotic thrombocytopenic purpura in the United States.卡泊珠单抗在美国免疫性血栓性血小板减少性紫癜中的成本效益
J Manag Care Spec Pharm. 2025 Mar;31(3):277-288. doi: 10.18553/jmcp.2025.31.3.277.
4
Raising Suspicion of Thrombotic Thrombocytopenic Purpura in a Patient With a Pre-existing Autoimmune Disease.提高对一名患有自身免疫性疾病患者血栓性血小板减少性紫癜的怀疑。
Cureus. 2025 Jan 18;17(1):e77623. doi: 10.7759/cureus.77623. eCollection 2025 Jan.
5
Multicenter Prospective Pilot Study Identifying Thrombomodulin as a Potential Biomarker for Neurocognitive Outcomes in Immune Thrombotic Thrombocytopenic Purpura.多中心前瞻性试点研究:确定血栓调节蛋白作为免疫性血栓性血小板减少性紫癜神经认知结局的潜在生物标志物
J Clin Med. 2025 Jan 22;14(3):694. doi: 10.3390/jcm14030694.
6
Real-World Data on Effectiveness and Safety of First-Line Use of Caplacizumab in Italian Centers for the Treatment of Thrombotic Thrombocytopenic Purpura: The Roscapli Study.意大利中心一线使用卡泊单抗治疗血栓性血小板减少性紫癜的有效性和安全性的真实世界数据:Roscapli研究
J Clin Med. 2024 Oct 31;13(21):6561. doi: 10.3390/jcm13216561.
7
Initial US tertiary health care system experience using caplacizumab in patients with immune thrombotic thrombocytopenic purpura.美国三级医疗保健系统中使用卡普拉珠单抗治疗免疫性血栓性血小板减少性紫癜患者的初步经验。
Ann Hematol. 2024 Nov;103(11):4449-4457. doi: 10.1007/s00277-024-05993-5. Epub 2024 Sep 11.
8
Caplacizumab improves clinical outcomes and is well tolerated across clinically relevant subgroups of patients with immune-mediated thrombotic thrombocytopenic purpura.卡泊单抗可改善临床结局,且在免疫介导的血栓性血小板减少性紫癜患者的临床相关亚组中耐受性良好。
Res Pract Thromb Haemost. 2024 Jul 15;8(5):102512. doi: 10.1016/j.rpth.2024.102512. eCollection 2024 Jul.
9
ADAMTS13 in the New Era of TTP.ADAMTS13 在 TTP 的新时代。
Int J Mol Sci. 2024 Jul 26;25(15):8137. doi: 10.3390/ijms25158137.
10
Clinical and economic burden of suspected thrombotic thrombocytopenic purpura in US hospitals.美国医院疑似血栓性血小板减少性紫癜的临床和经济负担。
Am J Health Syst Pharm. 2024 Dec 5;81(24):1278-1287. doi: 10.1093/ajhp/zxae167.

本文引用的文献

1
Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis.采用标准体重指数类别评估全因死亡率与超重和肥胖的关联:系统评价和荟萃分析。
JAMA. 2013 Jan 2;309(1):71-82. doi: 10.1001/jama.2012.113905.
2
ADAMTS13 deficiency exacerbates VWF-dependent acute myocardial ischemia/reperfusion injury in mice.ADAMTS13 缺乏症使小鼠的 VWF 依赖性急性心肌缺血/再灌注损伤加重。
Blood. 2012 Dec 20;120(26):5224-30. doi: 10.1182/blood-2012-06-440255. Epub 2012 Sep 14.
3
Autoimmune disorders in patients with idiopathic thrombotic thrombocytopenic purpura.特发性血栓性血小板减少性紫癜患者的自身免疫性疾病。
Hamostaseologie. 2012;32 Suppl 1:S86-9.
4
Protective anti-inflammatory effect of ADAMTS13 on myocardial ischemia/reperfusion injury in mice.ADAMTS13 对小鼠心肌缺血/再灌注损伤的保护抗炎作用。
Blood. 2012 Dec 20;120(26):5217-23. doi: 10.1182/blood-2012-06-439935. Epub 2012 Aug 22.
5
Comparison of risk prediction using the CKD-EPI equation and the MDRD study equation for estimated glomerular filtration rate.比较 CKD-EPI 方程和 MDRD 研究方程用于估计肾小球滤过率的风险预测。
JAMA. 2012 May 9;307(18):1941-51. doi: 10.1001/jama.2012.3954.
6
Body mass index and risk of cardiovascular disease, cancer and all-cause mortality.体重指数与心血管疾病、癌症和全因死亡率的风险。
Can J Public Health. 2012 Mar-Apr;103(2):147-51. doi: 10.1007/BF03404221.
7
Preventing depression: a global priority.预防抑郁症:全球优先事项。
JAMA. 2012 Mar 14;307(10):1033-4. doi: 10.1001/jama.2012.271.
8
Body-mass index and mortality among 1.46 million white adults.146 万白人成年人的体重指数与死亡率。
N Engl J Med. 2010 Dec 2;363(23):2211-9. doi: 10.1056/NEJMoa1000367.
9
Evidence of persistent neurologic injury following thrombotic thrombocytopenic purpura.血栓性血小板减少性紫癜后持续神经损伤的证据。
Am J Hematol. 2011 Jan;86(1):87-9. doi: 10.1002/ajh.21881.
10
Current depression among adults---United States, 2006 and 2008.当前成年人中的抑郁状况——美国,2006 年和 2008 年。
MMWR Morb Mortal Wkly Rep. 2010 Oct 1;59(38):1229-35.